 Connection
Paul Bunn to Follow-Up Studies
This is a "connection" page, showing publications Paul Bunn has written about Follow-Up Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.218 |
|
|
|
-
Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42.
Score: 0.041
-
Bunn PA. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004 Sep; 6(2):85-98.
Score: 0.032
-
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):e191-e204.
Score: 0.023
-
Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Bar?n AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 01; 13(1):134-138.
Score: 0.020
-
Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan; 9(1):96-104.
Score: 0.017
-
Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, B?hm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15; 20(12):3299-309.
Score: 0.016
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
Score: 0.014
-
Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA, Geraci MW, Miller YE. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila). 2011 Jun; 4(6):793-802.
Score: 0.013
-
Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, Franklin WA, Bunn PA, Varella-Garcia M, Hirsch FR. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol. 2007 Mar; 18(3):447-52.
Score: 0.009
-
Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
Score: 0.009
-
Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Cancer Treat Rep. 1984 Dec; 68(12):1439-46.
Score: 0.008
-
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Mar; 41(1-2):77-87.
Score: 0.006
-
Johnson BE, Ihde DC, Bunn PA, Becker B, Walsh T, Weinstein ZR, Matthews MJ, Whang-Peng J, Makuch RW, Johnston-Early A, et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med. 1985 Sep; 103(3):430-8.
Score: 0.002
-
Lichter AS, Bunn PA, Ihde DC, Cohen MH, Makuch RW, Carney DN, Johnston-Early A, Minna JD, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer. 1985 May 01; 55(9 Suppl):2163-75.
Score: 0.002
-
Ihde DC, Dunnick NR, Johnston-Early A, Bunn PA, Cohen MH, Minna JD. Abdominal computed tomography in small cell lung cancer: assessment of extent of disease and response to therapy. Cancer. 1982 Apr 01; 49(7):1485-90.
Score: 0.002
-
Bradley EC, Schechter GP, Matthews MJ, Whang-Peng J, Cohen MH, Bunn PA, Ihde DC, Minna JD. Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer. 1982 Jan 15; 49(2):221-3.
Score: 0.002
-
Minna JD, Bunn PA, Carney DN, Cohen MH, Cuttita F, Fosieck BE, Gazdar AF, Ihde DC, Johnston-Early A, Matthews MJ, Makuch R, Oie H, Rosen S, Lichter A, Glatstein E. Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bull Cancer. 1982; 69(1):83-93.
Score: 0.002
-
BUNN PA. Two-year follow up report of patients with miliary and meningeal tuberculosis treated with streptomycin. Am J Med Sci. 1950 Feb; 219(2):127-32.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|